Longitudinal Population-based Observational Study of COVID-19 in the UK Population (COVIDENCE UK)

June 6, 2025 updated by: Queen Mary University of London

COVIDENCE UK is a population-based observational longitudinal study that has the following objectives:

  1. To determine risk factors for incident COVID-19 and for adverse outcomes of COVID-19 in the UK population
  2. To characterise the natural history of COVID-19 in the UK population
  3. To evaluate the impact of COVID-19 on the physical and mental health of the UK population
  4. To provide a resource from which to identify potential participants for future clinical trials, and to use data collected in COVIDENCE as comparison or control data for trial participants who have been randomised to receive one or more interventions.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

13000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United Kingdom
    • County (optional)
      • London, County (optional), United Kingdom, E1 2AB
        • Recruiting
        • Queen Mary University of London
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

UK residents aged 16 years or more

Description

Inclusion Criteria:

  • UK resident
  • Age ≥16 years

Exclusion Criteria: none

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Incidence of confirmed COVID-19
Time Frame: 5 years
5 years

Secondary Outcome Measures

Outcome Measure
Time Frame
Incidence of probable or suspected COVID-19
Time Frame: 5 years
5 years
Incidence of COVID-19 requiring hospitalisation
Time Frame: 5 years
5 years
Incidence of COVID-19 requiring ventilatory support
Time Frame: 5 years
5 years
Incidence of fatal COVID-19
Time Frame: 5 years
5 years
Symptom duration per COVID-19 episode
Time Frame: 5 years
5 years
Symptom severity per COVID-19 episode
Time Frame: 5 years
5 years
Incidence of seroconversion to SARS-CoV-2
Time Frame: 5 years
5 years
Incidence of recurrent COVID-19
Time Frame: 5 years
5 years
EQ-5D-3L health-related quality of life score
Time Frame: 5 years
5 years
Health care costs associated with incident COVID-19
Time Frame: 5 years
5 years
Impact of the COVID-19 pandemic and the societal response on participants' financial status
Time Frame: 5 years
5 years
Incidence of COVID-19 on participant's physical health
Time Frame: 5 years
5 years
Impact of COVID-19 on participants' mental health
Time Frame: 5 years
5 years
Impact of COVID-19 on physical health of offspring born to participants during follow-up
Time Frame: 5 years
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Queen Mary University of London

Collaborators

London School of Hygiene and Tropical Medicine
King's College London
Queen's University, Belfast
Barts & The London NHS Trust
University of Edinburgh
Swansea University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 27, 2020

Primary Completion (Estimated)

April 27, 2026

Study Completion (Estimated)

April 27, 2026

Study Registration Dates

First Submitted

March 31, 2020

First Submitted That Met QC Criteria

March 31, 2020

First Posted (Actual)

April 1, 2020

Study Record Updates

Last Update Posted (Actual)

June 8, 2025

Last Update Submitted That Met QC Criteria

June 6, 2025

Last Verified

June 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • COVIDENCE UK

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe